Antiphospholipid antibodies (aPL) comprise a panel of autoantibodies that reflect a potential prothrombotic risk in several autoimmune conditions, most notably antiphospholipid (antibody) syndrome (APS). aPL can be divided into those that form part of the laboratory criteria for APS, namely, lupus anticoagulant (LA), as well as anticardiolipin antibodies (aCL) and anti-β2-glycoprotein I antibodies (aβ2GPI) of the immunoglobulin G and M classes, and those that form a group considered as “noncriteria antibodies.” The noncriteria antibodies include, for example, antiphosphatidylserine antibodies (aPS), antiprothrombin antibodies (aPT), and antiphosphatidylserine/prothrombin complex antibodies (aPS/PT). COVID-19 (coronavirus disease 2019) represents a prothrombotic disorder, and there have been several reports of various aPL being present in COVID-19 patients. There have also been similarities drawn between some of the pathophysiological features of COVID-19 and APS, in particular, the most severe form, catastrophic APS (CAPS). In this review, we critically appraise the literature on aPL and COVID-19. This is a companion piece to a separate review focused on LA. In the current review, we primarily concentrate on the so-called solid phase identifiable aPL, such as aCL and aβ2GPI, but also reflect on noncriteria aPL. We conclude that aPL positivity may be a feature of COVID-19, at least in some patients, but in general, identified “solid-phase” aPL are of low titer and not able to be well-linked to the thrombotic aspects of COVID-19. Also, most publications did not assess for aPL persistence, and where persistence was checked, the findings appeared to represent transient aPL. Importantly, high-titer aPL or multiple aPL positivity (including double, triple) were in the minority of COVID-19 presentations, and thus discount any widespread presence of APS, including the most severe form CAPS, in COVID-19 patients.

抗磷脂抗体 (aPL) 包含一组自身抗体，这些抗体反映了几种自身免疫性疾病中潜在的血栓形成风险，最显着的是抗磷脂（抗体）综合征 (APS)。aPL 可分为构成 APS 实验室标准的一部分，即狼疮抗凝剂 (LA)，以及免疫球蛋白 G 和 M 类的抗心磷脂抗体 (aCL) 和抗β2-糖蛋白 I 抗体 (aβ2GPI) ，以及那些构成被认为是“非标准抗体”的组。非标准抗体包括例如抗磷脂酰丝氨酸抗体(aPS)、抗凝血酶原抗体(aPT)和抗磷脂酰丝氨酸/凝血酶原复合物抗体(aPS/PT)。COVID-19（2019 年冠状病毒病）代表一种血栓形成前疾病，并且有几份报告称 COVID-19 患者中存在各种 aPL。COVID-19 和 APS 的一些病理生理特征之间也存在相似之处，特别是最严重的形式，即灾难性 APS (CAPS)。在这篇综述中，我们批判性地评估了关于 aPL 和 COVID-19 的文献。这是针对洛杉矶的另一篇评论的配套文章。在当前的审查中，我们主要关注所谓的固相可识别 aPL，例如 aCL 和 aβ2GPI，但也反映了非标准 aPL。我们得出结论，aPL 阳性可能是 COVID-19 的一个特征，至少在某些患者中是这样，但总的来说，已确定的“固相”aPL 滴度较低，不能与 COVID-19 的血栓形成方面密切相关。 19. 此外，大多数出版物没有评估 aPL 的持久性，在检查持久性的地方，发现似乎代表了短暂的 aPL。重要的是，高滴度 aPL 或多 aPL 阳性（包括双倍、三倍）在 COVID-19 表现中占少数，因此在 COVID-19 患者中低估了 APS 的任何广泛存在，包括最严重的形式 CAPS。